Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 RSV prophylaxis trial of clesrovimab vs palivizumab in high‑risk infants and young children
jRCT2031210664Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, single-blind trial of clesrovimab-cfor in respiratory syncytial virus disease (RSV) and respiratory syncytial virus lower respiratory tract infection (2 arms), sponsored by Merck & Co. Started Jul 2022; status: completed.
02
Drugs
clesrovimab-cfor
03
Conditions
respiratory syncytial virus disease (RSV)respiratory syncytial virus lower respiratory tract infection
Beyond the preview
Go deeper on jRCT2031210664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210664.